Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pharmacokinetic changes in renal failure].

V Launay-Vacher1, T Storme, H Izzedine

  • 1Service de Néphrologie, Groupe Hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, F75651 Paris. vincent.launay-vacher@psl.ap-hop-paris.fr

Presse Medicale (Paris, France : 1983)
|April 25, 2001
PubMed
Summary

Renal disease significantly alters drug pharmacokinetics, affecting absorption, distribution, and elimination. Dosage adjustments are crucial for patients with kidney impairment or undergoing dialysis to ensure drug safety and efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Pediatric exposure to endocrine disruptors and carcinogenic, mutagenic or reprotoxic substances by pharmaceutical forms intended for the cutaneous route: Regulatory provisions in France, in Europe, and state of the art of scientific knowledge].

Annales pharmaceutiques francaises·2021
Same author

Determination of the optimal dose of ephedrine in the treatment of arterial hypotension due to general anesthesia in neonates and infants below 6 months old: the ephedrine study protocol for a randomized, open-label, controlled, dose escalation trial.

Trials·2021
Same author

Population pharmacokinetics of ganciclovir after valganciclovir in renal transplant children.

Antimicrobial agents and chemotherapy·2019
Same author

Antibiotics and chronic kidney disease: Dose adjustment update for infectious disease clinical practice.

Medecine et maladies infectieuses·2019
Same author

Anticoagulants in frail patients. Seven situations at risk.

Journal de medecine vasculaire·2018
Same author

Renal function and venous thromboembolic diseases.

Journal des maladies vasculaires·2016

Area of Science:

  • Pharmacology
  • Nephrology
  • Drug Development

Context:

  • Drug pharmacokinetics are essential for safe and effective clinical development.
  • Renal disease introduces pathophysiological changes impacting drug absorption, distribution, metabolism, and elimination.
  • Patients with end-stage renal disease on dialysis may experience drug removal via extracorporeal procedures.

Purpose:

  • To outline potential alterations in drug pharmacokinetics in patients with renal insufficiency.
  • To emphasize the need for pharmacokinetic evaluation in renal failure.
  • To guide dosage and administration interval modifications for improved therapeutic outcomes.

Summary:

  • Renal insufficiency can alter drug absorption, distribution (including volume of distribution and plasma protein binding), and hepatic or renal metabolism.

Related Experiment Videos

  • The elimination of parent drugs and their metabolites can be significantly affected by kidney disease.
  • Pharmacokinetic studies are necessary for drugs primarily excreted unchanged in urine and for those metabolized in the liver, focusing on metabolite pharmacokinetics.

    • Impact:

    • Highlights the critical need for pharmacokinetic assessments in patients with renal impairment.
    • Informs necessary modifications in drug dosage and administration intervals for enhanced patient safety and treatment efficacy.
    • Provides a basis for optimizing drug therapy in individuals with compromised kidney function.